REFERENCES
1. Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer 2022;161:108-18.
2. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88.
3. Primrose JN, Fox RP, Palmer DH, et al. BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-73.
4. Zheng X, Chen B, Wu JX, et al. Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels. Cancer Manag Res 2018;10:3973-81.
5. Jiang W, Zeng ZC, Tang ZY, et al. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases. J Cancer Res Clin Oncol 2010;136:1323-31.
6. Sur MD, In H, Sharpe SM, et al. Defining the benefit of adjuvant therapy following resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2015;22:2209-17.
7. Lin YK, Hsieh MC, Wang WW, et al. Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy. Radiother Oncol 2018;128:575-83.
8. Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008;72:1495-501.
9. Kim YS, Oh SY, Go SI, et al. The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas. Cancer Chemother Pharmacol 2017;79:99-106.
10. Hammad AY, Berger NG, Eastwood D, et al. Is radiotherapy warranted following intrahepatic cholangiocarcinoma resection? the impact of surgical margins and lymph node status on survival. Ann Surg Oncol 2016;23:912-20.
11. Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an astro clinical practice guideline. Pract Radiat Oncol 2022;12:28-51.
12. Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
13. Oh D, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1:EVIDoa2200015.
14. Oh DY, He AR, Qin S, et al. 56P updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol 2022;33:S565-6.
15. Yamashita S, Koay EJ, Passot G, et al. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients. Cancer 2017;123:1354-62.
17. Verma V, Kusi Appiah A, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Lin C. Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base. J Gastrointest Oncol 2018;9:527-35.
18. Brunner TB, Blanck O, Lewitzki V, et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019;132:42-7.
19. De B, Tran Cao HS, Vauthey JN, et al. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: patterns of care and survival in the United States. Cancer 2022;128:2529-39.
20. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8.
21. Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer 2015;6:1099-104.
22. Smart AC, Goyal L, Horick N, et al. Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020;27:1122-9.
23. Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016;34:219-26.
24. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-64.
25. Weiner AA, Olsen J, Ma D, et al. Stereotactic body radiotherapy for primary hepatic malignancies-report of a phase I/II institutional study. Radiother Oncol 2016;121:79-85.
26. Pascher A, Jonas S, Neuhaus P. Intrahepatic cholangiocarcinoma: indication for transplantation. J Hepatobiliary Pancreat Surg 2003;10:282-7.
27. Chen X, Du J, Huang J, Zeng Y, Yuan K. Neoadjuvant and adjuvant therapy in intrahepatic cholangiocarcinoma. J Clin Transl Hepatol 2022;10:553-63.
28. Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020;12:693-708.
29. Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg 2018;42:2910-8.
30. Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlenther Onkol 2017;193:620-9.
31. Chuong MD, Kaiser A, Khan F, et al. Consensus report from the miami liver proton therapy conference. Front Oncol 2019;9:457.
32. Wang X, Krishnan S, Zhang X, et al. Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim 2008;33:259-67.
33. Petersen JB, Lassen Y, Hansen AT, Muren LP, Grau C, Høyer M. Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. Acta Oncol 2011;50:823-8.
34. Engelsman M, Schwarz M, Dong L. Physics controversies in proton therapy. Semin Radiat Oncol 2013;23:88-96.
35. Makita C, Nakamura T, Takada A, et al. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. Radiat Oncol 2014;9:26.
36. Ohkawa A, Mizumoto M, Ishikawa H, et al. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. J Gastroenterol Hepatol 2015;30:957-63.
37. Shimizu S, Okumura T, Oshiro Y, et al. Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy. Radiat Oncol 2019;14:241.
38. Hung SP, Huang BS, Hsieh CE, et al. Clinical outcomes of patients with unresectable cholangiocarcinoma treated with proton beam therapy. Am J Clin Oncol 2020;43:180-6.
39. Kim TH, Woo SM, Lee WJ, et al. Clinical efficacy of hypofractionated proton beam therapy for intrahepatic cholangiocarcinoma. Cancers 2022;14:5561.
40. Tryggestad EJ, Liu W, Pepin MD, Hallemeier CL, Sio TT. Managing treatment-related uncertainties in proton beam radiotherapy for gastrointestinal cancers. J Gastrointest Oncol 2020;11:212-24.
41. Bär E, Lalonde A, Royle G, Lu HM, Bouchard H. The potential of dual-energy CT to reduce proton beam range uncertainties. Med Phys 2017;44:2332-44.
42. Wroe AJ, Bush DA, Slater JD. Immobilization considerations for proton radiation therapy. Technol Cancer Res Treat 2014;13:217-26.
44. Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated proton therapy. Med Phys 2012;39:1079-91.
45. Hu YH, Harper RH, Deiter NC, et al. Analysis of the rate of re-planning in spot-scanning proton therapy. Int J Part Ther 2022;9:49-58.
46. Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions. Phys Med Biol 2008;53:1043-56.
47. Lomax AJ. Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. Phys Med Biol 2008;53:1027-42.
48. Bert C, Grözinger SO, Rietzel E. Quantification of interplay effects of scanned particle beams and moving targets. Phys Med Biol 2008;53:2253-65.
49. Zhang Y, Boye D, Tanner C, Lomax AJ, Knopf A. Respiratory liver motion estimation and its effect on scanned proton beam therapy. Phys Med Biol 2012;57:1779-95.
50. De Ruysscher D, Sterpin E, Haustermans K, Depuydt T. Tumour movement in proton therapy: solutions and remaining questions: a review. Cancers 2015;7:1143.
51. Lin B, Gao F, Yang Y, et al. FLASH radiotherapy: history and future. Front Oncol 2021;11:644400.
52. Montay-Gruel P, Acharya MM, Petersson K, et al. Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species. Proc Natl Acad Sci USA 2019;116:10943-51.
53. Vozenin MC, De Fornel P, Petersson K, et al. The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients. Clin Cancer Res 2019;25:35-42.
54. Favaudon V, Caplier L, Monceau V, et al. Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med 2014;6:245ra93.
55. Ruan JL, Lee C, Wouters S, et al. Irradiation at ultra-high (FLASH) dose rates reduces acute normal tissue toxicity in the mouse gastrointestinal system. Int J Radiat Oncol Biol Phys 2021;111:1250-61.
56. Mascia AE, Daugherty EC, Zhang Y, et al. Proton FLASH radiotherapy for the treatment of symptomatic bone metastases: the FAST-01 nonrandomized trial. JAMA Oncol 2023;9:62-9.
57. Raaymakers BW, Lagendijk JJ, Overweg J, et al. Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol 2009;54:N229-37.
58. Mutic S, Dempsey JF. The viewray system: magnetic resonance-guided and controlled radiotherapy. Semin Radiat Oncol 2014;24:196-9.
59. Raaymakers BW, Jürgenliemk-Schulz IM, Bol GH, et al. First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment. Phys Med Biol 2017;62:L41-50.
60. Rogowski P, von Bestenbostel R, Walter F, et al. Feasibility and early clinical experience of online adaptive mr-guided radiotherapy of liver tumors. Cancers 2021;13:1523.
61. Klüter S, Katayama S, Spindeldreier CK, et al. First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany. Strahlenther Onkol 2020;196:691-8.
62. Corradini S, Alongi F, Andratschke N, et al. MR-guidance in clinical reality: current treatment challenges and future perspectives. Radiat Oncol 2019;14:92.
63. Noel CE, Parikh PJ, Spencer CR, et al. Comparison of onboard low-field magnetic resonance imaging versus onboard computed tomography for anatomy visualization in radiotherapy. Acta Oncol 2015;54:1474-82.
64. Kurz C, Buizza G, Landry G, et al. Medical physics challenges in clinical MR-guided radiotherapy. Radiat Oncol 2020;15:93.
65. Mittauer K, Paliwal B, Hill P, et al. A new era of image guidance with magnetic resonance-guided radiation therapy for abdominal and thoracic malignancies. Cureus 2018;10:e2422.
66. Henke L, Kashani R, Robinson C, et al. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol 2018;126:519-26.
67. Feldman AM, Modh A, Glide-Hurst C, Chetty IJ, Movsas B. Real-time magnetic resonance-guided liver stereotactic body radiation therapy: an institutional report using a magnetic resonance-linac system. Cureus 2019;11:e5774.
68. Luterstein E, Cao M, Lamb JM, et al. Clinical outcomes using magnetic resonance-guided stereotactic body radiation therapy in patients with locally advanced cholangiocarcinoma. Adv Radiat Oncol 2019;5:189-95.
69. Rosenberg SA, Henke LE, Shaverdian N, et al. A multi-institutional experience of mr-guided liver stereotactic body radiation therapy. Adv Radiat Oncol 2019;4:142-9.
70. Chin RI, Schiff JP, Bommireddy A, et al. Clinical outcomes of patients with unresectable primary liver cancer treated with MR-guided stereotactic body radiation therapy: a Six-Year experience. Clin Transl Radiat Oncol 2023;41:100627.
71. Lamb J, Cao M, Kishan A, et al. Online adaptive radiation therapy: implementation of a new process of care. Cureus 2017;9:e1618.
72. Hall WA, Paulson E, Li XA, et al. Magnetic resonance linear accelerator technology and adaptive radiation therapy: an overview for clinicians. CA Cancer J Clin 2022;72:34-56.
73. Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future. Lancet Oncol 2020;21:e74-82.
74. Ding J, Zhang Y, Amjad A, et al. Deep learning based automatic contour refinement for inaccurate auto-segmentation in MR-guided adaptive radiotherapy. Phys Med Biol 2023;68:055004.
75. Güngör G, Serbez İ, Temur B, et al. Time analysis of online adaptive magnetic resonance-guided radiation therapy workflow according to anatomical sites. Pract Radiat Oncol 2021;11:e11-21.
76. van Houdt PJ, Yang Y, van der Heide UA, et al. Quantitative magnetic resonance imaging for biological image-guided adaptive radiotherapy. Front Oncol 2020;10:615643.
77. Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov 2019;9:1064-79.
78. Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021;6:803-15.
79. Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84.
80. Goyal L, Meric-Bernstam F, Hollebecque A, et al. FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388:228-39.
81. Ahmed MA, Selzer E, Dörr W, et al. Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer. Oncotarget 2016;7:69976-90.
82. Nuryadi E, Sasaki Y, Hagiwara Y, et al. Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy. Oncotarget 2018;9:32642-52.
83. Yoshimoto Y, Sasaki Y, Murata K, et al. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy. Gynecol Oncol 2020;159:546-53.
84. Ader I, Delmas C, Skuli N, et al. Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma. Eur J Cancer 2014;50:2351-9.
85. Verstraete M, Debucquoy A, Gonnissen A, et al. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer. BMC Cancer 2015;15:946.
86. Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol 2019;10:751-65.
87. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
88. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:796-807.
89. Tran AN, Lai A, Li S, et al. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol 2014;16:414-20.
90. Wang Y, Wild AT, Turcan S, et al. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Sci Adv 2020;6:eaaz3221.
91. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication [Last accessed on 15 Aug 2023].
92. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors [Last accessed on 15 Aug 2023].
93. Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin Oncol 2016;5:62.
94. Israel MA, Danziger N, McGregor KA, et al. Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns. Oncologist 2021;26:787-96.
95. Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions. Front Pharmacol 2018;9:185.
96. Liu ZL, Liu X, Peng H, et al. Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: a case report. Front Med 2020;7:368.
97. Zhao Q, Chen Y, Du S, et al. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 2021;22:175-83.
98. Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer 2019;7:204.
